Reactivity of the aorta and mesenteric resistance arteries from the obese spontaneously hypertensive rat: Effects of glitazones

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 4, 2011, Pages

  Mendizábal, Yolanda ^a   Llorens, Silvia ^a   Nava, Eduardo ^a  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Endothelial function; Metabolic syndrome

Indexed keywords

CREATININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDOMETACIN; INSULIN; LIPID; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N(G) NITROARGININE METHYL ESTER; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PIOGLITAZONE; PROSTACYCLIN; PROSTAGLANDIN F1 ALPHA; ROSIGLITAZONE; TEMPOL; THROMBOXANE A2; TRIACYLGLYCEROL; UREA;

ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; AORTA; ARTICLE; BLOOD VESSEL DIAMETER; BLOOD VESSEL FUNCTION; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR FUNCTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE CONTRACTILITY; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; VASCULAR RESISTANCE;

ANIMALS; AORTA; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; HYPOGLYCEMIC AGENTS; MALE; MESENTERIC ARTERIES; MICROCIRCULATION; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; OBESITY; PROSTAGLANDINS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SUPEROXIDES; THIAZOLIDINEDIONES; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS;

EID: 80053231622     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01280.2010     Document Type: Article

References (32)

1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553, 1998.
2. Aleixandre de AA, Miguel CM. Experimental rat models to study the metabolic syndrome. Br J Nutr 102: 1246-1253, 2009.
3. de Jongh RT, Serne EH, IJzerman RG, de VG, Stehouwer CD. Impaired microvascular function in obesity: implications for obesityassociated microangiopathy, hypertension, and insulin resistance. Circulation 109: 2529-2535, 2004.
4. Diederich D, Yang ZH, Buhler FR, Luscher TF. Impaired endotheliumdependent relaxations in hypertensive resistance arteries involve cyclooxygenase pathway. Am J Physiol Heart Circ Physiol 258: H445-H451, 1990.
5. Dinerman JL, Lawson DL, Mehta JL. Interactions between nitroglycerin and endothelium in vascular smooth muscle relaxation. Am J Physiol Heart Circ Physiol 260: H698-H701, 1991.
6. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet 366: 1279-1289, 2005.
7. Ernsberger P, Koletsky RJ, Friedman JE. Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of syndrome X. Ann NY Acad Sci 892: 272-288, 1999.
8. Frisbee JC, Stepp DW. Impaired NO-dependent dilation of skeletal muscle arterioles in hypertensive diabetic obese Zucker rats. Am J Physiol Heart Circ Physiol 281: H1304-H1311, 2001.
9. 2+, and superoxide anion levels. J Pharmacol Exp Ther 328: 19-27, 2009.
10. Katsumori K, Wasada T, Kuroki H, Arii H, Saeki A, AOKIK, Saito S, Omori Y. Prevalence of macro- and microvascular diseases in noninsulin- dependent diabetic and borderline glucose-intolerant subjects with insulin resistance syndrome. Diabetes Res Clin Pract 29: 195-201, 1995.
11. King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 23: 557, 2000.
12. King GL, Buzney SM, Kahn CR, Hetu N, Buchwald S, Macdonald SG, Rand LI. Differential responsiveness to insulin of endothelial and support cells from micro- and macrovessels. J Clin Invest 71: 974-979, 1983.
13. Kojima M, Asano M, Aoki K, Yamamoto M, Matsuda T. Decrease in α1-adrenoceptor reserve in mesenteric arteries isolated from spontaneously hypertensive rats. J Hypertens 7: 873-878, 1989.
14. Koletsky S. Obese spontaneously hypertensive rats-a model for study of atherosclerosis. Exp Mol Pathol 19: 53-60, 1973.
15. Komers R, Vrana A. Thiazolidinediones-tools for the research of metabolic syndrome X. Physiol Res 47: 215-225, 1998.
16. Llorens S, Mendizabal Y, Nava E. Effects of pioglitazone and rosiglitazone on aortic vascular function in rat genetic hypertension. Eur J Pharmacol 575: 105-112, 2007.
17. Lohray BB, Bhushan V, Rao BP, Madhavan GR, Murali N, Rao KN. Novel euglycemic and hypolipidemic agents. 1. J Med Chem 41: 1619-1630, 1998.
18. Marañón G. Ü ber Hypertonie and Zuckerkrankheit. Zentralblatt Innere Medizin 43: 169-176, 1922.
19. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs 62: 1463-1480, 2002.
20. Mensah GA, Mokdad AH, Ford E, Narayan KM, Giles WH, Vinicor F, Deedwania PC. Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol Clin 22: 485-504, 2004.
21. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41: 19-26, 1977.
22. Munzel T, Hink U, Yigit H, Macharzina R, Harrison DG, Mulsch A. Role of superoxide dismutase in in vivo and in vitro nitrate tolerance. Br J Pharmacol 127: 1224-1230, 1999.
23. Perez-Ortiz JM, Llorens S, Llopis J, Tranque P, Nava E. Potential benefits of glitazones for cancer and vascular disease. Curr Drug Ther 3: 111-125, 2008.
24. Pershadsingh HA. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs 13: 215-228, 2004.
25. Petrica L, Petrica M, Vlad A, Dragos JC, Gluhovschi G, Ianculescu C. Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wien Klin Wochenschr 121: 765-775, 2009.
26. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988.
27. Serne EH, de Jongh RT, Eringa EC, IJzerman RG, Stehouwer CD. Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension 50: 204-211, 2007.
28. Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes 52: 2867-2873, 2003.
29. Vigili de KS, Kiwanuka E, Tiengo A, Avogaro A. Visceral obesity is characterized by impaired nitric oxide-independent vasodilation. Eur Heart J 24: 1210-1215, 2003.
30. Wiernsperger NF. In defense of microvascular constriction in diabetes. Clin Hemorheol Microcirc 25: 55, 2001.
31. Xiang L, Dearman J, Abram SR, Carter C, Hester RL. Insulin resistance and impaired functional vasodilation in obese Zucker rats. Am J Physiol Heart Circ Physiol 294: H1658-H1666, 2008.
32. Yki-Jarvinen H, Utriainen T. Insulin-induced vasodilatation: physiology or pharmacology? Diabetologia 41: 369-379, 1998.